Late-stage win sets up regulatory talks and could reshape how cancer is treated - and how biotech investors value mRNA platforms.

If the claim holds up, personalized phage therapy could become a new frontline weapon against antibiotic resistance - but proof is far from final.

All-cash acquisition delivers divesiran, a late-stage-ready experimental treatment, to Merck KGaA's pipeline.

CEO Piotr Babieno explains how stability and trust, not one-off hits, convinced Nintendo to back Onyx: The Dark Grip, the first third-party horror exclusive in over a decade.

The band's first full-scale concerts since the Sphere residency kick off in Mexico City, São Paulo, and Buenos Aires with Beck supporting.

Pioneer Labs CEO Erika DeBenedictis is engineering microbes to terraform Mars, turning a sci-fi dream into a biotech business model.